Brooklyn ImmoTherapeutics LLC (NYSE: BTX) reported that is has acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. This will include an extensive patented process to develop gene editing compounds by utilizing mRNA which preclinical data has demonstrated a high level of efficiency. mRNA cell reprogramming is considered the highest efficiency and footprint free technology that may be applied to allogeneic and autologous cells.
“As a result of the license acquisition, Brooklyn is now poised to become a key player among companies exploring gene editing for cell therapies. This mRNA gene editing technology has the potential to be disruptive given its high efficiency and relatively low manufacturing costs. We look forward to continuing the work begun by Factor Bioscience and Novellus with this platform and to reporting our progress as our products advance towards the clinic,” commented Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President of Brooklyn. “Our licensing of this technology represents a significant advancement in our approach to treating cancers, blood and other disorders, and transforms us from a single therapeutic company with multiple potential indications to a platform company with multiple products in a pipeline of next-generation engineered cellular medicines.”